Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.

Next Previous
Trial Profile

Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use

Most Recent Events

  • 22 Oct 2011 Results presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
  • 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top